Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
63.45
+0.38 (0.60%)
At close: Nov 17, 2026
Shanghai OPM Biosciences Revenue
Shanghai OPM Biosciences had revenue of 285.05M CNY in the quarter ending September 30, 2026, with 203.96% growth. This brings the company's total for the last twelve months to 822.13M, up 132.96% year-over-year. In the year 2025, Shanghai OPM Biosciences had annual revenue of 354.91M with 19.40% growth. That makes Shanghai OPM Biosciences the 21,157th largest company in the world by revenue and 3,880th in China.
Revenue (ttm)
822.13M
Revenue Growth
+132.96%
P/S Ratio
10.93
Revenue / Employee
8.06M
Employees
102
Market Cap
9.04B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Shanghai OPM Biosciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 354.91M | 57.67M | 19.40% |
| Dec 31, 2024 | 297.24M | 54.12M | 22.26% |
| Dec 31, 2023 | 243.12M | -51.24M | -17.41% |
| Dec 31, 2022 | 294.37M | 81.68M | 38.41% |
| Dec 31, 2021 | 212.68M | 87.71M | 70.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.74B |
| Pacific Shuanglin Bio-pharmacy | 2.42B |
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.16B |
| Shanghai Medicilon | 1.54B |
| Liaoning Chengda Biotechnology | 1.34B |
| Chongqing Genrix Biopharmaceutical | 800.98M |
| Mabwell (Shanghai) Bioscience | 717.80M |